CORDIS
EU research results

CORDIS

English EN

Upscaling human insulin-producing beta cell production by efficient differentiation and expansion of endoderm progenitors

Project information

Grant agreement ID: 602889

Status

Closed project

  • Start date

    1 January 2014

  • End date

    31 December 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 860 730,20

  • EU contribution

    € 5 962 644

Coordinated by:

KOBENHAVNS UNIVERSITET

Denmark

Objective

Despite progress in producing beta cells from human pluripotent stem cells (hPSCs) in recent years, full differentiation cannot be obtained in vitro. The HumEn project hypothesises that a fundamental understanding of the coupling between endodermal progenitor expansion and differentiation is relevant for elucidating how to a) generate glucose-responsive beta cells from hPSCs in vitro, and b) generate sufficient number of beta cells to meet future clinical needs in cell therapy in diabetes. Thus, the overall aim of HumEn is to identify, understand, and expand human endodermal progenitors as a consistent and renewable source of cells for pancreatic beta cells differentiation.
We will focus on precursors from two stages of pancreatic differentiation; anterior definitive endoderm (ADE) and pancreatic endoderm (PE) progenitors, providing mechanistic insight into the signalling pathways and downstream targets that control their expansion and functional maturation into human beta cells. Rigorous in vitro (regulated insulin-release) and in vivo (protection against experimentally induced diabetes in mice) testing of insulin-producing cells will ensure a functional end product. The consortium proposes to address these problems by a unique combination of models and experimental approaches, including genetic, surface/biomaterial screens (3D), and cell surface antibody screens as well as cell signalling-to-transcription factor/chromatin effectors. In the end, HumEn aims to deliver a reliable and scalable protocol for directed differentiation of hPSCs into bona fide beta cells. The results of the project will not only provide answers to fundamental questions, but also deliver new concepts and knowledge of general importance for coordination of cell cycle progression and regulation of cell fate specification in stem cells/progenitors.
HumEn is highly innovative and carries excellent potential for translational output.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KOBENHAVNS UNIVERSITET

Address

Norregade 10
1165 Kobenhavn

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 935 725

Administrative Contact

Bjarne Friis Ploumark (Mr.)

Participants (8)

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 485 927

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 914 892

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 441 020

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 503 369

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 514 700

CYTOO SA

France

EU Contribution

€ 423 560

MATERIOMICS BV

Netherlands

EU Contribution

€ 537 965

MILTENYI BIOTEC GMBH

Germany

EU Contribution

€ 205 486

Project information

Grant agreement ID: 602889

Status

Closed project

  • Start date

    1 January 2014

  • End date

    31 December 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 860 730,20

  • EU contribution

    € 5 962 644

Coordinated by:

KOBENHAVNS UNIVERSITET

Denmark